Literature DB >> 35145263

Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape.

Samik Upadhaya, Svetoslav T Neftelinov, Jeffrey Hodge, Jay Campbell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35145263     DOI： 10.1038/d41573-022-00030-4

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   112.288


× No keyword cloud information.
  11 in total

Review 1.  Structure-based virtual screening for PDL1 dimerizers: Evaluating generic scoring functions.

Authors:  Viet-Khoa Tran-Nguyen; Saw Simeon; Muhammad Junaid; Pedro J Ballester
Journal:  Curr Res Struct Biol       Date:  2022-06-09

2.  Long-Term Cardiac Disease- and Cancer-Associated Mortalities in Patients With Non-Metastatic Stomach Adenocarcinoma Receiving Resection and Chemotherapy: A Large Competing-Risk Population-Based Cohort Study.

Authors:  Lei Huang; Yan Shi; Ya Jie Zhao; Lei Wang; Wei Guo Hu; Zheng Gang Zhu; Jun Zhang
Journal:  World J Oncol       Date:  2022-04-12

3.  Survival Prognosis, Tumor Immune Landscape, and Immune Responses of PPP1R18 in Kidney Renal Clear Cell Carcinoma and Its Potentially Double Mechanisms.

Authors:  Yi Wang; Shouyong Liu; Yinhao Chen; Bingye Zhu; Qianwei Xing
Journal:  World J Oncol       Date:  2022-02-28

Review 4.  Combination Approaches to Target PD-1 Signaling in Cancer.

Authors:  Emily K Moore; Marianne Strazza; Adam Mor
Journal:  Front Immunol       Date:  2022-07-14       Impact factor: 8.786

5.  Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments.

Authors:  Radoslaw Kitel; Ismael Rodríguez; Xabier Del Corte; Jack Atmaj; Magdalena Żarnik; Ewa Surmiak; Damian Muszak; Katarzyna Magiera-Mularz; Grzegorz M Popowicz; Tad A Holak; Bogdan Musielak
Journal:  ACS Chem Biol       Date:  2022-09-08       Impact factor: 4.634

Review 6.  Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer.

Authors:  Ofek Mussafi; Jie Mei; Wenjun Mao; Yuan Wan
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

Review 7.  Emerging Trends in Immunotherapy for Cancer.

Authors:  Alok K Mishra; Amjad Ali; Shubham Dutta; Shahid Banday; Sunil K Malonia
Journal:  Diseases       Date:  2022-09-06

Review 8.  Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments.

Authors:  Qi Jiang; Mixue Xie; Ruyin Chen; Feifei Yan; Chanqi Ye; Qiong Li; Shuaishuai Xu; Wei Wu; Yunlu Jia; Peng Shen; Jian Ruan
Journal:  Front Immunol       Date:  2022-08-29       Impact factor: 8.786

9.  CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma.

Authors:  Zhang-Wei Hu; Wei Sun; Yi-Hui Wen; Ren-Qiang Ma; Lin Chen; Wen-Qing Chen; Wen-Bin Lei; Wei-Ping Wen
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786

10.  Sequence-specific 1H, 13C and 15N backbone NMR assignments for the N-terminal IgV-like domain (D1) and full extracellular region (D1D2) of PD-L1.

Authors:  Kayleigh Walker; Lorna C Waters; Geoff Kelly; Frederick W Muskett; Mark D Carr
Journal:  Biomol NMR Assign       Date:  2022-06-08       Impact factor: 0.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.